Q1 2022 Results

NEW INDICATIONS Company overview Financial performance Financial review 2022 priorities Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications LEAD INDICATIONS 2022 2023 sabatolimab¹ Lead MBG453 HR-MDS iptacopan LNP023 PNH ensovibep Lead SKO136 COVID19 tislelizumab VDT482 1L Nasopharyngeal Carcinoma tislelizumab VDT482 NSCLC Appendix Innovation: Clinical trials References Abbreviations 2024 2025 ≥2026 Lead JDQ443 JDQ443 Lead icenticaftor Lead 177 Lu-NeoB Lead ganaplacide Lead MIJ821 Lead QBW251 AAA603 KAF156 Acute depression 2/3L NSCLC (mono) COPD Multiple Solid Tumors Malaria uncomplicated remibrutinib Lead ligelizumab Lead branaplam Lead iscalimab Lead LOU064 QGE031 LMI070 CFZ533 PPY988 Geographic atrophy Lead CSU Food allergy Huntington's disease Sjögren's syndrome UNR844 Presbyopia Lead NIS793 Lead cipargamin Lead ianalumab Lead TNO155 Lead 1L Pancreatic cancer KAE609 VAY736 Solid tumors Malaria severe Sjögren's syndrome pelacarsen Lead CPK850 Lead libvatrep Lead tropifexor&licogliflozi Lead TQJ230 RP SAF312 LJN452 COSP NASH (combos) CVRR-Lp(a) YTB323 Lead ecleralimab Lead LNA043 Lead 2L Diffuse large B-cell lymphoma CSJ117 Asthma Knee osteoarthritis gevokizumab Lead LXE408 Lead VPM087 Visceral leishmaniasis 1st line CRC LCM Pluvicto LCM Pluvicto LCM Scemblix LCM Scemblix LCM ianalumab LCM remibrutinib LCM AAA617 AAA617 ABL001 ABL001 VAY736 LOU064 MHSPC CML 1L CML, 2L, pediatrics Lupus Nephritis Pre-taxane Sjögren's syndrome LCM iptacopan LCM sabatolimab LCM iptacopan LCM cipargamin LCM ianalumab LCM tislelizumab LCM LNP023 MBG453 C3G Unfit AML LNP023 aHUS KAE609 VAY736 VDT482 Malaria uncomplicated SLE Adj/Neo adj NSCLC iptacopan LCM tislelizumab LCM remibrutinib LCM JDQ443 LCM iscalimab LCM tislelizumab LCM VDT482 LNP023 IgAN 1L Small Cell Lung Cancer LOU064 Multiple sclerosis JDQ443 CFZ533 VDT482 NSCLC (combo) Liver Tx 1L Urothelial Cell Carcinoma tislelizumab LCM ianalumab LCM VAY736 iptacopan LNP023 LCM VDT482 1L Gastric Cancer AIH iMN tislelizumab LCM VDT482 1L ESCC tislelizumab LCM VDT482 Localized ESCC tislelizumab LCM VDT482 1L Hepatocellular Carcinoma 1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 42 Investor Relations | Q1 2022 Results NOVARTIS | Reimagining Medicine

View entire presentation